A new review suggests the menopause transition may mark a critical window for Alzheimer’s prevention in women, shifting focus toward earlier detection, sex-specific risk factors, and more personalized care.
Expert Review: Women’s midlife: the front line of Alzheimer prevention. Image Credit: izzuanroslan / Shutterstock
In a recent review published in The Journal of Clinical Investigation, author Dr. Lisa Mosconi, a neuroscientist and women’s brain health specialist, examined how midlife hormonal changes and neuroendocrine aging influence Alzheimer’s disease (AD) risk in women and identified opportunities for early, sex-specific prevention strategies.
Why Women Face Higher Alzheimer’s Risk
Nearly two-thirds of individuals affected by AD are women, raising a critical question: why are women more vulnerable? Traditionally, this has been linked to longer life expectancy, but new evidence suggests deeper biological causes. Hormonal changes in midlife, especially menopause, can change brain biology and metabolism and may contribute to amyloid plaques and tau tangles, which are key biological markers of AD.
By the year 2050, it is estimated that over 1.2 billion women will experience menopause; therefore, it is important to understand these changes. At this time, there is not a lot of research that has focused on sex-specific mechanisms; thus, there is an urgent need for additional studies on these topics.
Epidemiology and Sex Differences in AD
AD affects more than 55 million people globally, with projections exceeding 150 million by 2050. Women represent nearly two-thirds of these cases. While aging remains the strongest risk factor, female sex is the strongest risk factor for late-onset AD after advanced age. However, although pooled meta-analyses support a modest excess incidence in women, some studies have reported no incidence differences, so parts of the epidemiologic debate remain unsettled.
This difference cannot be determined solely by longevity, as biological, hormonal, and social factors also contribute. Notably, AD has today been acknowledged as a disease that starts many decades before it is manifested, mostly in midlife. This shifts attention toward earlier life stages, especially in women.
Menopause Driven Brain and Hormone Changes
Menopause is a major hormonal transition in which estrogen levels fall while follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rise. Estrogen protects the brain by lowering inflammation, increasing neuronal survival, supporting non-amyloidogenic processing, and reducing amyloid-beta-related neurotoxicity. When estrogen levels drop during menopause, and FSH and LH levels increase, these changes may promote processes linked to AD development.
Research on brain imaging shows that postmenopausal women exhibit greater amyloid-beta deposition, lower cerebral glucose metabolism, and reduced gray matter volume compared with premenopausal women and men. Such results suggest that menopause can serve as a biological tipping point in brain aging, although some findings may also partly reflect aging itself rather than menopause alone.
Reproductive Health Factors and Dementia Risk
There are several reproductive health factors that affect AD risk. Early menopause, especially before age 45, is linked with increased risk of dementia. Oophorectomy (removal of ovaries) before natural menopause could increase long-term dementia risk, with the greatest excess risk seen at younger ages, especially before 45.
It is also noted that dementia risk is associated with a shorter reproductive span (between menarche and menopause), probably because it leads to less exposure to estrogen, although findings remain mixed across studies.
Women who experience polycystic ovary syndrome (PCOS) can experience an earlier onset of dementia. Parity (number of childbirths) shows a complex relationship; for example, having one to four children may lower risk, while having five or more may increase it.
Midlife Cognitive Symptoms and Early Signals
Many women report memory lapses, difficulty concentrating, or mental fog during perimenopause. Subjective cognitive decline (SCD) is often regarded as typical of the aging process; however, it may signal the onset of cognitive decline.
Empirical evidence supports this connection through various brain imaging analyses. Brain scans show that women who have SCD exhibit less structural integrity, particularly in brain areas known to be affected by AD, and also exhibit decreased functional connectivity between brain regions, along with lower levels of energy production in brain cells, although the mechanisms linking menopause-related SCD and AD remain under investigation.
Frequent vasomotor symptoms, especially around sleep, have also emerged as an underinvestigated midlife factor linked to AD-related risk, with studies cited in the review associating them with white matter hyperintensities and less favorable plasma amyloid biomarker profiles.
Hormone Therapy Timing and Alzheimer’s Prevention
Menopause hormone therapy (MHT), which includes estrogen therapy (ET) or combined estrogen-progestogen therapy (EPT), has been widely studied for its potential role in AD prevention.
Trials like the Women’s Health Initiative Memory Study (WHIMS) established that the initiation of MHT in older adults (aged 65-79) raised the risk of dementia. However, newer evidence suggests that timing is crucial. When initiated near menopause, MHT may reduce AD risk by 11% to 30%, but these findings come mainly from observational studies and should be interpreted cautiously because of possible bias and confounding.
This concept is known as the “timing hypothesis.” It proposes that hormone therapy is beneficial only if started during a critical window, typically within 10 years of menopause. Starting therapy too late may have neutral or harmful effects.
Current guidelines do not recommend MHT for preventing cognitive decline or dementia in the general population, though estrogen therapy near menopause may help preserve cognitive function in women with early menopause, especially after oophorectomy.
Genetic, Lifestyle, and Health Disparities
The apolipoprotein E epsilon 4 (APOE ε4) allele is considered the strongest genetic risk factor for AD; however, it may confer a greater risk in women than in men. Many common cardiovascular diseases, physical inactivity, and poor sleep become more frequent following menopause, and all three are associated with increased risk of cognitive impairment and can make up to 45% of global cases of AD.
Differences in health status also affect the likelihood of developing AD. Black women and Hispanic women are experiencing more menopausal symptoms as well as developing dementia at a greater rate than other groups, possibly due to a combination of biological and socioenvironmental factors, although more research is needed to determine whether these differences reflect underlying biological vulnerability or other causes.
Precision Prevention and Early Detection Strategies
Advances in biomarkers, such as blood-based biomarkers (BBBs), cerebrospinal fluid (CSF) analysis, and positron emission tomography (PET) imaging, allow the detection of AD pathology years before symptoms appear.
This opens the door to early intervention. By identifying women at risk during midlife, healthcare systems can implement targeted prevention strategies like hormone therapy, lifestyle changes, and personalized treatments based on genetic and hormonal profiles.
The review also emphasizes that current prevention frameworks are largely sex-aggregated and may underestimate women’s cumulative risk burden by failing to account for female-specific neuroendocrine and reproductive risk factors.
Conclusion and Future Research Directions
The study concludes that AD risk in women is likely to be shaped in part by midlife neuroendocrine changes rather than aging alone. Hormonal changes at menopause are a significant influence on brain health, as these hormone changes can contribute to increased risk for AD-related brain changes and neurodegenerative vulnerability.
Early menopause, reproductive history, subjective cognitive decline, and vasomotor symptoms are important indicators of possible elevated risk, though not definitive predictors on their own. Studies show that hormone therapy may provide benefits,t but its effectiveness may depend on the timing and biology of the woman.
This review shows the need for preventive approaches that are sex-specific, supported by stronger biomarkers, and tailored to women’s biology. The review also stresses that more longitudinal, biomarker-driven, and causal research is needed before menopause-related mechanisms can be treated as definitively established drivers of AD.
